Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)
Public ClinicalTrials.gov record NCT02609984. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1
Study identification
- NCT ID
- NCT02609984
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Enrollment
- 89 participants
Conditions and interventions
Conditions
Interventions
- CMB305 Biological
- atezolizumab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 28, 2015
- Primary completion
- Feb 5, 2019
- Completion
- Feb 5, 2019
- Last update posted
- Jul 6, 2020
2015 – 2019
United States locations
- U.S. sites
- 18
- U.S. states
- 16
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University Medical Center | Palo Alto | California | 94304 | — |
| Sarcoma Oncology Research Center | Santa Monica | California | 90403 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| MedStar Washington Hospital Center | Washington D.C. | District of Columbia | 20010 | — |
| Mayo Clinic of Jacksonville | Jacksonville | Florida | 32224 | — |
| Georgia Cancer Specialists | Sandy Springs | Georgia | 30342 | — |
| Northwestern University Feinburg School of Medicine | Chicago | Illinois | 60611 | — |
| University of Iowa Hospital and Clinics | Iowa City | Iowa | 52242 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 10029 | — |
| Washington University in St. Louis | St Louis | Missouri | 63110 | — |
| Monter Cancer Research | Lake Success | New York | 11042 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Duke Cancer Institute | Durham | North Carolina | 27710 | — |
| Fox Chase cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Vanderbilt University | Nashville | Tennessee | 37232 | — |
| University of Vermont Cancer Center | Burlington | Vermont | 05405 | — |
| Scca/Fhcrc | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02609984, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 6, 2020 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02609984 live on ClinicalTrials.gov.